ClinicalTrials.gg

Program

selatogrel

Also written as “Selatogrel”, “ACT-246475” and “Selatogrel 8 mg”.

Its studies are mostly in Myocardial Infarction · Coronary Artery Disease, led by 2 companies.

Furthest: phase 3, since Jun 28, 202111 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris101 open or runningphase 3since Jun 28, 2021Dec 20, 2017Jul 2027phase 3 · NCT04957719
Idorsia Pharmaceuticals10 open or runningphase 1since Sep 27, 2013Sep 27, 2013none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2013First study: phase 1 study in Safety, Tolerability, Pharmacokinetics and PharmacodynamicsNew to Idorsia PharmaceuticalsIdorsia Pharmaceuticals · NCT01954615 · 49 enrolled · France
  2. Dec 20, 2017Viatris's first study: phase 2 study in Stable Coronary Artery DiseaseNew to ViatrisViatris · NCT03384966 · 346 enrolled · United States, Canada, Denmark and more
  3. Jan 30, 2018Phase 1 study in HealthyViatris · NCT03430661 · 77 enrolled · United States
  4. Mar 26, 2018Phase 2 study in Acute Myocardial InfarctionViatris · NCT03487445 · 48 enrolled · Belgium, Israel, Switzerland
  5. Jul 10, 2018Phase 1 study in Healthy SubjectsViatris · NCT03593278 · 6 enrolled · Germany
  6. Jan 21, 2019Phase 1 study in Healthy SubjectViatris · NCT03814200 · 14 enrolled · Netherlands
  7. May 25, 2020Phase 1 study in Healthy SubjectsViatris · NCT04406896 · 24 enrolled · Germany
  8. Sep 7, 2020Phase 1 study in Healthy SubjectsViatris · NCT04557280 · 24 enrolled · United States
  9. Jun 28, 2021Phase 3 study in Acute Myocardial InfarctionViatris · NCT04957719 · 25,000 planned · United States, Australia, Austria and more
  10. Aug 13, 2025Phase 1 study in Healthy VolunteersViatris · NCT07133191 · 32 enrolled · United States
  11. May 22, 2026Phase 1 study in Chronic Coronary SyndromeViatris · NCT07615868 · 20 enrolled · China

Ahead

  1. Jul 2027Primary completion: phase 3 study in Acute Myocardial InfarctionViatris · NCT04957719

TargetBeta

P2RY12 →read by rule
“Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule

Other programs on P2RY12

ProgramCompanyFurthest phaseStudies
ClopidogrelruleSanofiphase 471
TicagrelorruleAstraZenecaphase 447

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07615868Chronic Coronary Syndrome · China1CompletedViatrisSep 19, 202620
NCT07133191Healthy Volunteers · United States1CompletedViatrisNov 5, 202532
NCT04957719Acute Myocardial Infarction · United States, Australia, Austria and more3By invitationViatrisJul 202725,000
NCT04557280Healthy Subjects · United States1CompletedViatrisDec 19, 202024
NCT04406896Healthy Subjects · Germany1CompletedViatrisOct 23, 202024
NCT03814200Healthy Subject · Netherlands1CompletedViatrisFeb 12, 201914
NCT03593278Healthy Subjects · Germany1CompletedViatrisAug 5, 20186
NCT03487445Acute Myocardial Infarction · Belgium, Israel, Switzerland2CompletedViatrisNov 10, 201848
NCT03430661Healthy · United States1CompletedViatrisMay 20, 201977
NCT03384966Stable Coronary Artery Disease · United States, Canada, Denmark and more2CompletedViatrisAug 18, 2018346
NCT01954615Safety, Tolerability, Pharmacokinetics and Pharmacodynamics · France1CompletedIdorsia PharmaceuticalsMar 201249

How it is read

Names in the registry

  • “Selatogrel”, 8 entries
  • “ACT-246475”, 3 entries
  • “Selatogrel 8 mg”, 1 entry
  • “Selatogrel 16 mg”, 1 entry
  • “ACT-246475 (Group G dose to be defined)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.